Sanofi SA reported a 0.2% decline in sales to €36.04 billion in 2020 as gains for specialty care medicines and vaccines were largely offset by a drop in sales for general medicines and consumer healthcare products. However operating profit more than trebled to €14 billion from €3 billion. This reflected gains from the sale of shares in Regeneron Pharmaceuticals Inc, Sanofi’s long-time development partner. In addition, an impairment charge taken in 2019 for a haemophilia product wasn’t repeated last year.
